. 2015 Mar 20;17(3):e71. doi: 10.2196/jmir.3582

Table 2.

Results of mixed design ANOVAs for the treatment and waiting list control groups at baseline, posttreatment, and 3-month follow-up: intention-to-treat analysis.

Outcome measures			Groups×pre-post, mean (SD)		F _1,157	P	d
			Treatment (n=79)	Control (n=80)
PDS
	Intrusion				30.74	<.001	0.72
		Baseline	8.32^a (3.98)	8.33^a (3.84)
		Posttreatment	5.09^b (4.33)	8.06^a (3.89)
		Follow-up	5.37^b (4.59)	—
	Avoidance				34.26	<.001	0.92
		Baseline	12.49^a (3.77)	12.80^a (3.82)
		Posttreatment	8.78^b (5.38)	13.04^a (3.78)
		Follow-up	8.97^b (5.15)	—
	Hyperarousal				28.58	<.001	0.68
		Baseline	9.54^a (3.07)	9.52^a (3.58)
		Posttreatment	6.42^b (4.19)	9.07^a (3.64)
		Follow-up	6.53^b (4.09)	—
	Total score				44.29	<.001	0.92
		Baseline	30.35^a (8.16)	30.65^a (8.10)
		Posttreatment	20.29^b (12.45)	30.17^a (8.70)
		Follow-up	20.87^b (12.37)	—
HSCL-25
	Anxiety				28.30	<.001	0.79
		Baseline	2.88^a (0.60)	2.92^a (0.61)
		Posttreatment	2.29^b (0.81)	2.85^a (0.61)
		Follow-up	2.39^b (0.76)	—
	Depression				40.66	<.001	1.03
		Baseline	3.04^a (0.58)	3.10^a (0.50)
		Posttreatment	2.36^b (0.90)	3.11^a (0.50)
		Follow-up	2.54^b (0.85)	—
SCL: Somatization					11.68	<.001	0.56
		Baseline	1.44^a (0.84)	1.50^a (0.90)
		Posttreatment	1.09^b (0.81)	1.56^a (0.88)
		Follow-up	1.11^b (0.82)	—
EUROHIS: Life satisfaction					44.20	<.001	0.84
		Baseline	2.33^a (0.73)	2.33^a (0.79)
		Posttreatment	2.97^b (0.95)	2.27^a (0.71)
		Follow-up	2.72^b (0.82)	—

^a Means within column grouping that share this superscript do not differ at P=.05.

^b Means within column grouping that share this superscript do not differ at P=.05.